Substituted 1,3-Dioxanes as Partial PPAR Gamma Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with PPAR modulation, such as diabetes and inflammation, face limitations due to side effects from full-agonist compounds like thiazolidinediones, necessitating the development of novel compounds that are not necessarily full-agonists and can effectively modulate PPAR gamma, thromboxane receptors, and thromboxane synthase.
Innovation Solution
Development of specific 2,4-diphenyl-1,3-dioxane compounds that can modulate PPAR gamma, thromboxane receptors, and thromboxane synthase, offering partial agonist properties to treat conditions like diabetes, inflammation, and cardiovascular disorders with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full-agonist compounds like thiazolidinediones are used to treat diabetes and inflammation, then therapeutic efficacy is improved, but side effects worsen
Solution Approach 1:
The patent applies partial agonism by designing compounds that provide partial activation of PPAR-gamma receptors rather than full agonist activity. This partial action mechanism achieves therapeutic efficacy for diabetes and inflammation while avoiding the excessive activation that causes severe side effects like weight gain, cardiac hypertrophy, and edema associated with full-agonist thiazolidinediones
Solution Approach 2:
The patent modifies the pharmacological parameters of PPAR-gamma modulation by introducing compounds with specific molecular structures (2,4-diphenyl-1,3-dioxane core) that change the activation profile from full to partial agonism. This parameter change in receptor activation intensity allows maintaining therapeutic benefits while reducing harmful effects
2Object-affected harmful factors
If novel compounds with partial agonist properties are developed, then side effects are reduced, but therapeutic efficacy may be compromised
Solution Approach 1:
The patent achieves multi-functionality by designing compounds that simultaneously modulate PPAR-gamma activity, antagonize thromboxane receptors, and inhibit thromboxane synthase. This universal approach allows a single compound class to address multiple therapeutic targets (diabetes, inflammation, cardiovascular protection) with partial agonist properties, maintaining efficacy across different conditions while reducing side effects
Data Source
AI summary
Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.